Eli Lilly’s senior vice president and chief financial officer Josh Smiley announced plans for the Indianapolis-based pharmaceutical company to spend from $1 billion to $5 billion each quarter during 2020 to bolster the drug manufacturer’s product pipeline.
Eli Lilly and Co. plans to sell two versions of insulin products at half their current U.S. list prices, eight months after the drug manufacturer started selling a half-priced version of the widely used Humalog injection.
The U.S. Food and Drug Administration approved Novo Nordisk’s Fiasp (insulin aspart injection) 100 u/mL for use as a new mealtime insulin option for children with diabetes.
Novo Nordisk will offer free, one-time supply of insulin to people in immediate need and at risk of rationing the medication.
Sanofi is ending diabetes and cardiovascular (DCV) research efforts as part of a revamp to narrow the number of the company’s business units in the hope of bolstering growth and profit.
The U.S. Food and Drug Administration approved an expanded indication for Sanofi’s Toujeo (insulin glargine injection) for blood sugar control in adult and pediatric patients who are ages 6 years and older. The expanded indication approved by the FDA applies to both type 1 and 2 diabetes. Previously, Toujeo was U.S.-approved only for adults aged 18 years and older.
Researchers Working to Understand Why Some Patients with Autoimmune Diseases Develop Diabetes Instead of ArthritisArthritis, Autoimmune Diseases, Autoimmune inflammation, Beta cells, Diabetes, Genes, Immune Cells, Inflammatory Bowel Disease, Insulin, Multiple Sclerosis, National Institutes of Health, Nature Genetics, Pancreatic beta cells, Pluripotential cells, Researchers, Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Type 1 Diabetes
Recently published research in the journal Nature Genetics found significant insight into this question: Why does a patient with an autoimmune disease become a type 1 diabetic rather than have rheumatoid arthritis?
Eli Lilly will add 100 jobs to the company’s manufacturing facilities at the Lilly Technology Center campus in Indianapolis.
Independent experts on an FDA advisory panel voted against the use of an already approved drug from Eli Lilly and Boehringer Ingelheim as an add-on to insulin therapy for type 1 diabetes.
Danish drugmaker Novo Nordisk is aiming for a big slice of the multibillion-dollar diabetes market with a new pill approved by U.S. authorities that caters for patients with an aversion to needles.